Crystalline forms of a brutons tyrosine kinase inhibitor

  • US 10,752,634 B2
  • Filed: 04/01/2020
  • Issued: 08/25/2020
  • Est. Priority Date: 06/04/2012
  • Status: Active Grant
First Claim
Patent Images

1. A pharmaceutical formulation for oral administration comprising:

  • (a) about 140 mg of 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one;

    (b) one or more diluents;

    (c) one or more surfactants; and

    (d) one or more lubricants.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×